Thank you for submitting your manuscript for consideration by the EMBO Journal. We have now received a full set of referee reports on your manuscript, which are included below for your information.
As you can see from the comments, reviewers #1 and #3 express interest in the presented role of ciliary LKB1 in regulation of inflammation in polycystic kidneys. However, all three referees also raise substantive concerns with the analysis that would need to be addressed before they can support publication here. Based on the overall interest expressed in the reports I would like to invite you to submit a revised version of your manuscript in which you address the comments of all three referees. Please note that it is The EMBO Journal policy to allow only a single major round of revision and that it is therefore important to resolve the main concerns at this stage.
We generally allow three months as standard revision time, but the revision period can be extended to six months in the case of extensive revisions. Please contact us in advance if you would need an additional extension. As a matter of policy, competing manuscripts published during this period will not negatively impact on our assessment of the conceptual advance presented by your study. However, please contact me as soon as possible upon publication of any related work to discuss how to proceed.
Please feel free to contact me if have any further questions regarding the revision. Thank you for the opportunity to consider your work for publication. I look forward to your revision.
------------------------------------------------Referee #1:
In the present study, Viau and co-authors investigated the interaction between the primary cilium of kidney cells and inflammation processes in cilia-related kidney disorders. Here, they uncovered an essential role of LKB1 for normal kidney functioning, and showed that loss of LKB1 leads to a CCL2 chemokine release with subsequent recruitment of immune cells, and also that this process is absolutely dependent on the primary cilium. This is a very interesting area, which to date remains poorly investigated. Overall, this study is novel and has a significant impact in understanding the mechanisms underlying the cilia signaling and cilia-related disorders.
The data shown in the study are generally of high quality, however there are some points to address: Fig 1J is associated with reduced size of the kidney. Most ciliopathies are associated with increased size of the kidney. What is the critical difference here?
Loss of Lkb1 in Supp
2. The authors report that deletion of Lkb1 does not result in induction of AMPK or mTOR by microarray, and hence some other event must be important for renal pathology (Fig 4) . The explanation for this lack of transcriptional effect is likely the observation made in the past by some of the authors, which has shown that Lkb1 at the cilia indeed regulates AMPK and mTOR in a physiologically important way, through phosphorylation occurring at the basal body (PMID:20972424), in a manner that controls renal cell growth. Many other important biological events regulating cystic phenotypes also occur at the cilia and basal body, but do not necessarily affect transcriptional readouts. The authors should emphasize that pathology does not necessarily require changes in the transcription of regulated proteins, to integrate their current and past work.
3. The mechanism of CCL2 production control by LKB1 has been already reported for cancer cells, as the authors note (PMID: 26413869). However, the authors for the first time demonstrated specific cooperation between LKB1 and PKD1 controls CCL2 signaling, suggesting that disruption of this mechanism has an effect on ADPKD progression, a ciliopathy which is characterized by chronic inflammation and fibrosis. A puzzling part of this observation is the fact that many cancer cells lose ciliation, making it hard to understand how the same signaling mechanism can be observed in ciliated renal cells and likely unciliated endometrial cancer cells, particularly when loss of cilia in the current study results in reduced CCL2 signaling. The authors should reconcile these data. The results should be discussed in the context of the broader findings, that CCL2/MCP-1 induction is broadly linked to cystogenesis arising from multiple stimuli. Is the major new idea that CCL2 release and macrophage infiltration distinguish the more aggressive pathology of cysts associated with defective ciliary signaling, versus the less aggressive phenotype seen with loss of cilia? This should be better developed, and supported with some experiments.
5. It is also of interest that Ta and colleagues using a model of NPHP9-dependent cystic kidneys have shown that sirolimus inhibits the LKB1 regulated protein mTORC1, reducing disease pathology but not CCL2 expression (PMID:27723777). This also may inform mechanism, and could add to the discussion.
Minor point. 1. Figure 5B . Could the authors enlarge the images demonstrating the localization of LKB1 in the primary cilium?
Referee #2: General Summary In this manuscript, the authors conclude that Pkd1 and an Lkb1-based module comprising Lkb1/NPHP1/ANKS3/NEK7 form a functional unit that inhibits a ciliary Ccl2 inducing signal, which otherwise leads to inflammation and PKD progression in Lkb1 or Pkd1 deficient mice. They based this conclusion on the following observations. 1) A proteomic screen of Lkb1 precipitates identified Stradα and 30 other proteins that included the NPHP1-binding ANKS3 as well as NEK7 (known to interact with ANKS3); 2) NPHP1 and Lkb1 functionally interact in cystogenesis in zebrafish; 3) Ccl2 (Mcp1) and ANKRD1 are upregulated based on comparisons of microarray analysis in Lkb1 mutant kidneys at 5 weeks with RNA seq. in Lkb1-silenced MDCK; 4) Ccl2 is increased in Lkb1ΔTub kidneys at 5 weeks and in Lkb1-silenced MDCK, and neutrophils and CCR2+ Mø (but not T, B or total F4/80hiCD11b+ Mø) are increased in Lkb1ΔTub kidneys at 10 weeks; 5) Conditional silencing of Stradβ (but not Stradα) in MDCK increased Ccl2, and coablation of cilia together with Lkb1 prevented the increase in Ccl2 in Lkb1-silenced MDCK. Finally the authors showed that Pkd1 co-IP with Lkb1 and both Strads (α>>>β) in HEK293, and that ablated cilia in Pkd1 null MDCK cells or in 12 week iPkd1ΔTub iKif3aΔTub mice decreased Ccl2 expression and kidney CCR2+ Mø.
Specific concerns (can also be transmitted to the authors) Despite the extensive data presented, the paper do not convincingly support the authors major conclusion that a ciliary Pkd1 Lkb1-based complex regulates Ccl2 and that this Ccl2 is the elusive cilia-dependent cyst activating signal. First, Lkb1 expression in the kidney is massive (Fig. 1A ) and its role cannot be accounted for by expression in cilia, unless its knockdown is limited to cilia, which has not been done. Second, it is unclear that the Lkb1-based module comprising Lkb1/NPHP1/ANKS3/NEK7 or Stradβ is cilia-limited as none of these proteins are expressed ONLY in cilia. Third, the relevance of the zebrafish data is suspicious as zebrafish pronephros does not have nonmotile primary cilia that are found in mammalian kidneys. Forth, identification of Ccl2 was based on the unusual comparison of microarray analysis in Lkb1 mutant kidneys at 5 weeks with RNA seq in the Lkb1-silenced canine cell line MDCK; no protein expression has been determined in any experiment presented, and cyst fluid in ADPKD patients contains several other cytokines. Fifth, the authors show that infiltration of CCR2+ macrophages (Fig 4D) but not total macrophages (Suppl. Fig. 6 J) is increased in Lkb1Δ Tub kidneys at 10 weeks. How significant is this subpopulation? What percent it represents of the total infiltrating Mø? Sixth, Stradβ does not bind Lkb1 in the absence of MO25, and PKd1 associates much better with Stradα (reportedly not involved in Ccl2 expression). Finally, how do these data explain the differences in clinical presentation of NPHP where inflammation and subsequent fibrosis appear early and are much more prominent than cysts vs. ADPKD if Ccl2 is the common factor in cystogenesis?
This is an interesting manuscript that addressed the role of ciliary LKB1 in regulating chemokine signalling, macrophages and tissue homeostasis in polycystic kidney disease (PKD). Viau et al found that deletion of LKB1 in renal tubular cells not only disrupted renal morphology and function but also induced the expression of chemokine CCL2, resulting in the recruitment and activation of macrophages in kidneys. This study provided integrated evidences to link ciliary LKB1 to renal inflammation, in which LKB1 in the primary cilia of renal tubular epithelial cells was involved in macrophage infiltration and played an important role in the progress of ADPKD or NPHP. However, several concerns need to be addressed.
Major concerns:
1. In Fig.1 the authors provided evidences that deletion of LKB1 affected kidney morphology and function. Some panels in this figure are confused and need to be reorganized by adding the missing controls. In Fig. 1C , the kidneys sizes were not diminished as mentioned in MRI analysis. In Fig.  1F , is it to be implied that the control kidney sections (for 14 and 23 weeks) do not change from the 5 week time point? 2. In Fig. 2 , the authors found that LKB1 interacted with ANKS3, NPHP1 and NEK7 in kidney medulla and HEK 293 cells. In Fig. 5 , depletion of NPHP1, ANKS3 or NEK7 resulted in upregulation of Ccl2 in MDCK cells. Does knockdown of NPHP1, ANKS3, and NEK7 affect the protein level and activity of LKB1? 3. In Fig. 6 , the authors found that LKB1 also interacted with polycystin-1 (PC1) to form a functional unit to contribute to the progression of disease. Does deletion of PC1 affect the expression and activity of LKB1, ANKS3, NPHP3 as well as NEK7 in the PKD1 mutant cells and kidneys compared to the control? Does PKD1 mutation induce the decrease of LKB1 and the module proteins, leading to increase of Ccl2 expression in in PKD1 mutant cells and the subsequent recruitment of macrophages in PKD1 mutant kidneys. In addition, the effect of double knockout of Pkd1 and LKB1 on cyst growth, the expression of Ccl2 and the recruitment of macrophages in kidneys need to be added in Fig. 6 to strength the role of LKB1 in PKD.
4. The authors provided evidence that LKB1/NPHP1/ANKS3/NEK7 complex controls Ccl2 expression. Is Ccl2 expression in PKD1 mutant also LKB1 dependent?
5. What's the mechanism of LKB1 in regulating the expression of Ccl2. It is unclear how LKB1 inhibits Ccl2 expression at homeostasis or upregulates Ccl2 expression in Pkd1 mutant kidneys. Please justify.
Minor concerns: In Fig. 6 , it should be "Polycystin 1 (PC1)" interacts with LKB1 but not "PKD1", which is the gene name but not the protein name. The size of PC1 in Fig. 6a needs to be double checked. We thank the reviewers for their careful assessment of our submission and for thoughtful comments which we address here in full. The process has helped to further strengthen of our findings and results in an improved manuscript.
Referee #1:
The data shown in the study are generally of high quality, however there are some points to address: 2. The authors report that deletion of Lkb1 does not result in induction of AMPK or mTOR by microarray, and hence some other event must be important for renal pathology (Fig 4) . The explanation for this lack of transcriptional effect is likely the observation made in the past by some of the authors, which has shown that Lkb1 at the cilia indeed regulates AMPK and mTOR in a physiologically important way, through phosphorylation occurring at the basal body (PMID:20972424), in a manner that controls renal cell growth. Many other important biological events regulating cystic phenotypes also occur at the cilia and basal body, but do not necessarily affect transcriptional readouts. The authors should emphasize that pathology does not necessarily require changes in the transcription of regulated proteins, to integrate their current and past work.
We agree with the reviewer, that transcriptional read-outs are not an adequate way to assess mTOR activity. This is reflected in Suppl. Figure 4 (now Appendix Fig S2 - 
expression (Fig EV3E). This suggests that phosphorylation of AMPK by LKB1 at the basal body may affect CCL2 in addition to mTOR. We agree that the question of the precise role of mTOR in PKD is important, and realize that many investigations are conducted to this end. Since our manuscript has a different focus and due to the large number of data that the manuscript contains, we decided against discussing this point further in the text.
Since the review process will be published alongside the paper, in case it is accepted, the readers interested in this point will be able to follow the discussion here.
3. The mechanism of CCL2 production control by LKB1 has been already reported for cancer cells, as the authors note (PMID: 26413869). However, the authors for the first time demonstrated specific cooperation between LKB1 and PKD1 controls CCL2 signaling, suggesting that disruption of this mechanism has an effect on ADPKD progression, a ciliopathy which is characterized by chronic inflammation and fibrosis. A puzzling part of this observation is the fact that many cancer cells lose ciliation, making it hard to understand how the same signaling mechanism can be observed in ciliated renal cells and likely unciliated endometrial cancer cells, particularly when loss of cilia in the current study results in reduced CCL2 signaling. The authors should reconcile these data. (Fig  7 and Fig EV5) . These findings strengthen the concept that lack of PKD1 interferes with the control of a ciliary CCL2 inducing signal, leading to inflammation and more rapid cyst growth.
This is a very interesting point. Ciliation is heterogeneous across different cancers and not uniform for any type of malignancy. Indeed HeLa cells, which are derived from a highly aggressive cervical cancer contain cilia (PMID: 26074404). Endometrial cancer is mentioned and has been shown to contain cilia (PMID: 29206870). While the number of ciliated cells in that paper
We thank the reviewer for mentioning this reference. It is interesting that in their model CCL2 regulation was independent of rapamycin, suggesting that it does not occur downstream of mTOR.
Since the model in the cited paper is based on an NPHP9 mutation we decided against discussing it in our manuscript. We have not tested NPHP9 and find that not all of the NPHPs we examined bind to LKB1. We suggest leaving the role of NPHP9 to be defined in future studies.
We have now added enlargements of cilia in this subfigure (Fig 5D) .
General Summary In this manuscript, the authors conclude that Pkd1 and an Lkb1-based module comprising Lkb1/NPHP1/ANKS3/NEK7 form a functional unit that inhibits a ciliary Ccl2 inducing signal, which otherwise leads to inflammation and PKD progression in Lkb1 or Pkd1 deficient mice. They based this conclusion on the following observations. 1) A proteomic screen of Lkb1 precipitates identified Stradα and 30 other proteins that included the NPHP1-binding ANKS3 as well as NEK7 (known to interact with ANKS3); 2) NPHP1 and Lkb1 functionally interact in cystogenesis in zebrafish; 3) Ccl2 (Mcp1) and ANKRD1 are upregulated based on comparisons of microarray analysis in Lkb1 mutant kidneys at 5 weeks with RNA seq. in Lkb1-silenced MDCK; 4) Ccl2 is increased in Lkb1ΔTub kidneys at 5 weeks and in Lkb1-silenced MDCK, and neutrophils and CCR2+ Mø (but not T, B or total F4/80hiCD11b+ Mø) are increased in Lkb1ΔTub kidneys at 10 weeks; 5) Conditional silencing of Stradβ (but not Stradα) in MDCK increased Ccl2, and coablation of cilia together with Lkb1 prevented the increase in Ccl2 in Lkb1-silenced MDCK. Finally the authors showed that Pkd1 co-IP with Lkb1 and both Strads (α>>>β) in HEK293, and that ablated cilia in Pkd1 null MDCK cells or in 12 week iPkd1ΔTub iKif3aΔTub mice decreased Ccl2 expression and kidney CCR2+ Mø.
Specific concerns (can also be transmitted to the authors) Despite the extensive data presented, the paper do not convincingly support the authors major conclusion that a ciliary Pkd1 Lkb1-based complex regulates Ccl2 and that this Ccl2 is the elusive cilia-dependent cyst activating signal. First, Lkb1 expression in the kidney is massive (Fig. 1A) and its role cannot be accounted for by expression in cilia, unless its knockdown is limited to cilia, which has not been done. (Fig 7 and Fig EV5) . This supports our model that tubular secretion of CCL2 plays a patho-physiologically meaningful role in ADPKD.
Fifth, the authors show that infiltration of CCR2+ macrophages (Fig 4D) but not total macrophages (Suppl. Fig. 6 J) is increased in Lkb1Δ Tub kidneys at 10 weeks. How significant is this subpopulation? What percent it represents of the total infiltrating Mø?
This is indeed an important question and we thank the reviewer for raising this. Our data show that about 20% of total kidney macrophages (defined as F4/80hiCD11b+Ly6C-Ly6G-) at homeostasis express CCR2. In Lkb1 deficient mice this population increases to about 30%. We have added this information in Appendix Fig S5L. This represents a biologically relevant fraction of macrophages and supports the observations on the Pkd1/Ccl2 targeted mice.

Sixth, Stradβ does not bind Lkb1 in the absence of MO25,
We do not show that STRADb does not bind LKB1 in the absence of MO25.
and PKd1 associates much better with Stradα (reportedly not involved in Ccl2 expression).
The reviewer presumably refers to Fig. 6A. This experiment tests the interaction of PKD1 with STRAD in an overexpression system (tagged constructs in HEK 293T cells). It demonstrates that PKD1 can interact with STRADa as well as STRADb. Since the interaction is not between endogenous proteins, the strength of interaction does not reflect physiological amounts. Please note that the input of Flag-PC1 is stronger in the STRADa lanes compared to STRADb lanes, which may explain why more STRADa is detected in the IP compared to STRADb. Our findings do not rule out that PKD1 interacts with STRADa outside the cilium in a functional way.
Finally, how do these data explain the differences in clinical presentation of NPHP where inflammation and subsequent fibrosis appear early and are much more prominent than cysts vs.
ADPKD if Ccl2 is the common factor in cystogenesis?
This is an important point and has been raised by other reviewers as well. Our data suggest that increased CCL2 drives macrophage numbers. This can have different effects depending on context. In ADPKD, macrophages promote cyst growth in epithelia that are prone to cystogenesis due to other effects of PKD1 loss which our manuscript does not address. In other words, the difference between the models is that the PKD1 mutation confers a pro-cystogenic phenotype on epithelial cells that does not occur in LKB1 mutated kidneys (and presumably not in NPHP1 mutation either). The hypothesis that cyst formation occurs through different mechanisms in ADPKD and NPHP has been raised by others (PMID: 28320755). However, in both cases macrophages drive fibrosis and nephron loss. In addition cyst growth (not cyst initiation) is fueled in ADPKD. While macrophages and fibrosis occur early in ADPKD, their presence is hidden by the much more prominent cysts. We have now tested this hypothesis by targeting PKD1 together with tubular CCL2 in the kidney. This strongly ameliorated cyst growth (Fig 7 and Fig EV5) but did not prevent cyst formation altogether and thus supports our hypothesis. With respect to ADPKD, our findings are in line with previous data by others: (1) macrophages drive cyst growth in genetic models of PKD (PMID: 21921140). (2) ablation of cilia in ADPKD models ameliorates the phenotype (PMID: 23892607). Parts of the results section and the discussion have been rewritten to accentuate these issues.
Referee #3:
Major concerns: 1. In Fig.1 the authors provided evidences that deletion of LKB1 affected kidney morphology and function. Some panels in this figure are confused and need to be reorganized by adding the missing controls. In Fig. 1C , the kidneys sizes were not diminished as mentioned in MRI analysis. In Fig.  1F , is it to be implied that the control kidney sections (for 14 and 23 weeks) do not change from the 5 week time point?
We thank the reviewer for pointing out that in Fig 1C the 2. In Fig. 2 , the authors found that LKB1 interacted with ANKS3, NPHP1 and NEK7 in kidney medulla and HEK 293 cells. In Fig. 5 , depletion of NPHP1, ANKS3 or NEK7 resulted in upregulation of Ccl2 in MDCK cells. Does knockdown of NPHP1, ANKS3, and NEK7 affect the protein level and activity of LKB1?
To address this question we performed western blots for LKB1, AMPK, and p-AMPK in cells after knock-down of NPHP1, ANKS3 and NEK7. We did not find altered expression of LKB1 or different amounts of p-AMPK (Appendix Fig. S4 A -C and I -K).
3. In Fig. 6 , the authors found that LKB1 also interacted with polycystin-1 (PC1) to form a functional unit to contribute to the progression of disease. Does deletion of PC1 affect the expression and activity of LKB1, ANKS3, NPHP3 as well as NEK7 in the PKD1 mutant cells and kidneys compared to the control? Does PKD1 mutation induce the decrease of LKB1 and the module proteins, leading to increase of Ccl2 expression in in PKD1 mutant cells and the subsequent recruitment of macrophages in PKD1 mutant kidneys. In addition, the effect of double knockout of Pkd1 and LKB1 on cyst growth, the expression of Ccl2 and the recruitment of macrophages in kidneys need to be added in Fig. 6 to strength the role of LKB1 in PKD. (Fig EV3H) . (Fig 7 and Fig EV5) and thus links PKD1 and CCL2 to disease progression in-vivo.
We examined but did not find consistent differences in the expression of ANKS3, NEK7 or NPHP1 in PKD1 knock-out cells (new data: Appendix Fig S4D, F -H). LKB1 expression was not decreased and no difference was observed in p-AMPK (Appendix Fig S4D, E, L). In PKD1 targeted kidneys no difference was observed with regards to the expression of LKB1, ANKS3, NEK7 or NPHP1 (Appendix Fig S4M -P). This leads us to conclude that altered expression of members of the CCL2 regulating complex do not account for the observed increase in CCL2 expression in PKD1 mutated cells or kidneys. We thank the reviewer for asking about the simultaneous deletion of PKD1 and LKB1. This is an instructive experiment, as it may delineate if PKD1 is required for the activity of the LKB1 regulatory complex or not. We engineered PKD1 knock-out cells to express tetracycline inducible shRNA against LKB1 (Appendix Fig S3S). We found CCL2 expression to be increased in these cells at a similar level compared to PKD1 knock-out cells with intact LKB1
This is not the case as is indicated in point #3.
5. What's the mechanism of LKB1 in regulating the expression of Ccl2. It is unclear how LKB1 Minor concerns:
In Fig. 6 , it should be "Polycystin 1 (PC1)" interacts with LKB1 but not "PKD1", which is the gene name but not the protein name. The size of PC1 in Fig. 6a needs to be double checked. Thank you for submitting a revised version of your manuscript. It has now been seen by two of the original referees (#1 and 3) whose comments are shown below. As you will see they both find that all criticisms have been sufficiently addressed and recommend the manuscript for publication. However, before we can officially accept the manuscript there are a few editorial issues concerning text and figures that I need you to address.
• Please include your response to the following point raised by the referee #2 in the manuscript text. Below is the point of the referee #2: Referee point: Forth, identification of Ccl2 was based on the unusual comparison of microarray analysis in Lkb1 mutant kidneys at 5 weeks with RNA seq in the Lkb1-silenced canine cell line MDCK; Your response: The strength of our chosen comparison between LKB1 mutant kidneys and LKB1 silenced cells lies in the advantage that we were able to discard regulated transcripts from the kidney that came from outside of renal epithelia. A case in point is CCL2, which might have been discarded based on the assumption that it is derived from infiltrating immune cells. Including transcriptional data from LKB1 silenced cells in the analysis indicated that CCL2 is expressed in the tubular epithelial cell as a consequence of LKB1 loss.
• Please make sure to address the remaining concerns raised by the referee #3 in both point-by-point response file and corresponding changes in the text.
Based on the revisions, the manuscript is significantly improved, and has thoroughly and substantively addressed points I originally raised.
Referee #3:
This study tried to link ciliopathy to inflammation through a LKB1. The authors found that deletion of LKB1 in renal tubular cells induced the expression of chemokine CCL2, which resulted in the recruitment and activation of macrophages in kidneys, contributing to ciliopathy. The authors addressed the reviewers' concerns point-by-point in the rebuttal letter but some concerns were not clearly answered. In addition, Flowers et al., has published a paper entitled "Lkb1 deficiency confers glutamine dependency in polycystic kidney disease" (Nature Comm. Volume 9, 814, 2018).
The major concerns still need to be addressed:
1. Regarding the downstream signaling of LKB1, the authors originally stated that "deletion of Lkb1 does not result in induction of AMPK or mTOR by microarray, and hence some other event must be important for renal pathology", and now they thought "that phosphorylation of AMPK by LKB1 at the basal body may affect CCL2 in addition to mTOR." Please clarify.
2. It seems that deletion of Pkd1 alone is enough to affect the expression of Ccl2. If this is the case, a. how to explain the upregulation of Ccl2 in ADPKD if the expression and activity of LKB1 didn't change. b. did it mean that the upregulation of Ccl2 is not LKB1 dependent in ADPKD? c. what is the functional role of the interaction between PKD1 and LKB1?
3. As the authors mentioned there are two independent pathways to regulate the Ccl2 expression in PKD. One is Pkd1 dependent, and another is LKB1/NPHP1/ANKS3/ NEK7 unit dependent, which are not associated and function in parallel. The authors stated that "The lack of a further increase of CCL2 upon depletion of LKB1 in PKD1 knock-out cells suggests that loss of PKD1 fully deregulates CCL2 and indicates that LKB1 requires PKD1 for its CCL2 regulating function." It is not clear how these two pathways works in ADPKD and in NPHP. Whether LKB1 works in NPHP as the authors proposed in ADPKD.
4. It was pointed out that the mechanism of CCL2 production control by LKB1 has been already reported for cancer cells (PMID: 26413869), which suggested that LKB1 could regulate CCL2 expression with mechanisms independent of PC1. Since LKB1 should be presented in both ciliated and non-ciliated cells, whether LKB1 in non-ciliated cells, such as IFT88 and Kif3a knockout cells, also regulated the expression of Ccl2.
5. The authors found that removal of the cilium decreases CCL2, irrespective of LKB1, suggesting that the cilium receives a positive signal inducing CCL2. In this case how to explain the regulation of Ccl2 by LKB1 in the mouse models published by Somlo's lab (Nat Genet. 45 (9): 1004-1012. 2013).
6. The zebrafish data did not provide any support to the study in mammalian kidneys and in this study.
2nd Revision -authors' response 13 May 2018
1. Regarding the downstream signaling of LKB1, the authors originally stated that "deletion of Lkb1 does not result in induction of AMPK or mTOR by microarray, and hence some other event must be important for renal pathology", and now they thought "that phosphorylation of AMPK by LKB1 at the basal body may affect CCL2 in addition to mTOR." Please clarify. Figure 8 gives a detailed depiction of our model and a summary of our findings.
4. It was pointed out that the mechanism of CCL2 production control by LKB1 has been already reported for cancer cells (PMID: 26413869), which suggested that LKB1 could regulate CCL2 expression with mechanisms independent of PC1. Since LKB1 should be presented in both ciliated and non-ciliated cells, whether LKB1 in non-ciliated cells, such as IFT88 and Kif3a knockout cells, also regulated the expression of Ccl2. Any descriptions too long for the figure legend should be included in the methods section and/or with the source data.
In the pink boxes below, please ensure that the answers to the following questions are reported in the manuscript itself. Every question should be answered. If the question is not relevant to your research, please write NA (non applicable). We encourage you to include a specific subsection in the methods section for statistics, reagents, animal models and human subjects.
definitions of statistical methods and measures:
a description of the sample collection allowing the reader to understand whether the samples represent technical or biological replicates (including how many animals, litters, cultures, etc.).
Please fill out these boxes ê (Do not worry if you cannot see all your text once you press return) a specification of the experimental system investigated (eg cell line, species name).
C-Reagents
B-Statistics and general methods
the assay(s) and method(s) used to carry out the reported observations and measurements an explicit mention of the biological and chemical entity(ies) that are being measured. an explicit mention of the biological and chemical entity(ies) that are altered/varied/perturbed in a controlled manner.
Data
the data were obtained and processed according to the field's best practice and are presented to reflect the results of the experiments in an accurate and unbiased manner. figure panels include only data points, measurements or observations that can be compared to each other in a scientifically meaningful way. graphs include clearly labeled error bars for independent experiments and sample sizes. Unless justified, error bars should not be shown for technical replicates. if n< 5, the individual data points from each experiment should be plotted and any statistical test employed should be justified the exact sample size (n) for each experimental group/condition, given as a number, not a range;
Each figure caption should contain the following information, for each panel where they are relevant:
Captions
The data shown in figures should satisfy the following conditions:
Source Data should be included to report the data underlying graphs. Please follow the guidelines set out in the author ship guidelines on Data Presentation.
YOU MUST COMPLETE ALL CELLS WITH A PINK BACKGROUND ê see below
A biostatistician was consulted. unpaired t-test, 2-sided; p =.05, power 80%, standardized effect size 1.06.
No samples were excluded from analysis. "Materials and Methods, Statistical analysis subsection".
No method of randomization was used to determine how samples were allocated. "Materials and Methods, Statistical analysis subsection".
Animal studies were not randomized.
Investigators were blinded during the experiment or analysis. "Materials and Methods, Statistical analysis subsection".
Mice phenotypic analysis was done in a blinded fashion. "Materials and Methods, Statistical analysis subsection".
yes
For cell culture, the normal distribution of experiment replicates was systematically assumed. For animal studies, the aspect of the distribution was used to assume or not the normal distribution.
yes Differences in variance were determined when multiple groups were compared by ANOVA "Materials and Methods, Statistical analysis subsection".
F-Data Accessibility
D-Animal Models E-Human Subjects
We confirm compliance
G-Dual use research of concern
see "Materials and Methods, Data availability subsection" See Appendix Tables S1 to S5 See "Materials and Methods, Antibodies subsection". 
